Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
27.16
-0.98 (-3.48%)
At close: Oct 31, 2025, 4:00 PM EDT
27.17
+0.01 (0.04%)
After-hours: Oct 31, 2025, 7:59 PM EDT
Moderna Employees
Moderna had 5,800 employees as of December 31, 2024. The number of employees increased by 200 or 3.57% compared to the previous year.
Employees
5,800
Change (1Y)
200
Growth (1Y)
3.57%
Revenue / Employee
$530,690
Profits / Employee
-$500,517
Market Cap
10.61B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5,800 | 200 | 3.57% |
| Dec 31, 2023 | 5,600 | 1,700 | 43.59% |
| Dec 31, 2022 | 3,900 | 1,200 | 44.44% |
| Dec 31, 2021 | 2,700 | 1,400 | 107.69% |
| Dec 31, 2020 | 1,300 | 470 | 56.63% |
| Dec 31, 2019 | 830 | 70 | 9.21% |
| Dec 31, 2018 | 760 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MRNA News
- 1 day ago - Moderna: Focus On Cancer Vaccines, Not Buyout - Seeking Alpha
- 1 day ago - Moderna (MRNA) Stock Is Trading Lower Friday: What's Going On? - Benzinga
- 2 days ago - S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna Surges - Investopedia
- 9 days ago - Moderna Named a Top Employer by Science for Eleventh Consecutive Year - Accesswire
- 9 days ago - Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection - Benzinga
- 9 days ago - Moderna to Host Investor Event - Analyst Day - Accesswire
- 10 days ago - Moderna ends development of CMV vaccine after trial failure - Reuters
- 10 days ago - Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - Accesswire